Gender Equity and Vertically Transmitted Infections: A Country-Level Analysis Across 153 Countries

Youngmi Lee,1 Junseok Park,1 Myeungki Min,1 Youjin Lee,1 Youngun Yu,1 Mi Kyoung Shim,1 and Myeong Gyu Kim2,3,*

Abstract
Purpose: Gender inequality is a barrier to education toward women and accessibility to health facilities, which are important for preventing vertical transmission. This study was conducted to analyze the impact of gender equity on vertically transmitted infections (hepatitis viruses, human immunodeficiency virus [HIV], and syphilis) using country-level indicators.

Methods: The relationship between the Global Gender Gap Index (GGGI), which is indicator of gender equity, and vertical transmission was analyzed. GGGI scores were collected from 153 countries in 2020. Vertical transmission included 10 outcomes for hepatitis viruses, HIV, and syphilis. Generalized linear model (GLM) was used for analyzing the relationship. Other predictors included skilled birth attendant and country income.

Results: The median GGGI score was 0.706 (interquartile range, 0.664–0.736). GLM showed that the GGGI score was significantly associated with the incidence of both chronic hepatitis B and C in under 5 years (both \( p < 0.001 \)). For HIV, GGGI score was significantly associated with the pregnant women with unknown HIV status (\( p = 0.001 \)), no early infant diagnosis (\( p = 0.027 \)), and final transmission rate (\( p = 0.005 \)). There was no significant predictor for pregnant women who have not received antiretroviral therapy for prevention of mother-to-child transmission. All syphilis indicators have improved in high-income countries compared to low-income countries. GGGI score had a significant association only with no syphilis screening (\( p < 0.001 \)).

Conclusions: A lower GGGI score was associated with higher vertical transmission of hepatitis and HIV. The improvement of gender equity might prevent vertical transmission of these viruses. Further intervention studies are warranted to verify the results.

Keywords: gender equity; vertical transmission; hepatitis virus; HIV; syphilis

Introduction
Women’s empowerment and gender equity are an elemental human right and crucial to achieving well-being.1 Substantial progress has been accomplished toward women’s empowerment and gender equity in accordance with the Millennium Development Goals (MDGs) declaration.2,3 Nevertheless, in some parts of the world, women and girls continue to suffer discrimination.3 The gender gaps may arise in the following areas: health, educational attainment, economic participation, labor opportunities, political empowerment, and supportive laws and institutions.4 The Global Gender Gap Index (GGGI) measures gender gaps in economic participation/opportunity, educational attainment, health/survival, and political empowerment.4 The GGGI scores range from 0 to 1, with 0 meaning complete gender inequality and 1 meaning complete gender equity.4 Promoting gender equity and empowering women have been known as the key to women’s and maternal health.5 Women’s empowerment may also affect the childrens’ and adolescents’ health. For this reason, researchers have studied the relationships between health

1College of Pharmacy, CHA University, Pocheon, Republic of Korea.
2College of Pharmacy, Ewha Womans University, Seoul, Republic of Korea.
3Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, Republic of Korea.

*Address correspondence to: Myeong Gyu Kim, PhD, College of Pharmacy, Graduate School of Pharmaceutical Sciences, Ewha Womans University, S2 Ewhayeodae-gil, Seoul 03760, Republic of Korea, E-mail: kimmg@ewha.ac.kr

© Youngmi Lee et al., 2021; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
outcomes and gender equity. A systematic review evaluated the impact of gender equity on both women’s and men’s health across the 48 studies. In this review, greater gender equity has positive effects on health outcomes such as mental health and self-rated health. Gender inequality prevented utilization of maternal delivery care and increased maternal mortality ratios. In addition, gender inequality was associated with lower prevalence of contraceptive use among adolescents, increased adolescent birth rate, and increased neonatal, infant, and under 5-year mortalities.

Vertical transmission, which is known as mother-to-child transmission, influences children’s health and includes human immunodeficiency virus (HIV) infection, hepatitis B, hepatitis C, and syphilis. Preventing delivery with unknown infections and prevention of mother-to-child transmission (PMTCT) are required to save children and eradicate vertically transmitted infections from the world. To be aware of the necessity of testing and treatment and to be able to receive management during pregnancy are, therefore, important for pregnant women. Gender inequality is a barrier to education toward women and accessibility to health facilities. Few studies have evaluated relationships between country-level gender equity and vertically transmitted infections. Even that focused on the prevalence of infections, especially HIV infection, in women of childbearing age or people who inject drugs rather than on transmission to children. Thus, the aim of this study was to analyze the impact of gender equity on vertically transmitted infections using country-level indicators.

**Methods**

IRB approval was waived because national statistics without personal information were used.

**Data**

The Global Gender Gap Report 2020 reported GGGI scores and its subindices. This study included 153 countries where the GGGI score was reported in 2020. Country income and skilled birth attendant (SBA), which could contribute to maternal and child health, were investigated as confounding factors. Country income, gross national income (GNI) per capita in 2019, which was calculated using World Bank Atlas method, was collected from the World Bank database. Country income, which is a continuous variable, was converted into a categorical variable. Country income was classified into four groups: GNI per capita of >12,536 USD for high income (HI); 4046–12,535 USD for upper-middle income (UMI); 1036–4045 USD for lower-middle income; and ≤1035 USD for low income (LI). SBA refers to the percentage of births attended by skilled health personnel and the most recent value was used.

**Outcomes**

In this study, 10 vertical transmission outcomes for hepatitis viruses, HIV, and syphilis in 2017 were evaluated.

For hepatitis viruses, incidence of chronic hepatitis B and that of hepatitis C in under 5-year old (cases per 100,000) were investigated because the risk of acquiring chronic hepatitis is greatest in the perinatal period, with up to 90% of infected newborns becoming chronic carriers.

Four outcomes for HIV were selected: pregnant women with unknown HIV status (%), pregnant women who have not received antiretroviral therapy (ART) for PMTCT (%), no early infant diagnosis defined as testing within 2 months of birth (%), and final transmission rate, including breastfeeding period.

For syphilis, maternal syphilis prevalence (%), no syphilis screening (%), no syphilis treatment (%), and congenital syphilis rate (cases per 100,000 live births) were investigated.

Some percentage outcomes are contrary to those reported in the literature. The data for those outcomes were taken from 100 minus the percentage value reported in the literature.

**Statistical analysis**

The data did not meet the assumption of a multiple linear regression that the residuals are normally distributed. Alternatively, a generalized linear model (GLM), which allows for considerable flexibility, was used for analyzing the relationship between the set of predictors and response variable. Predictors included GGGI score or subindices, SBA, and country income. GGGI and subindex were exclusively included in the model, taking into account multicollinearity. LI group was used as the reference in the GLM analysis.

The distribution of the response variable, Yi, was described as gamma or inverse-Gaussian families of distribution, which were suitable for the right-skewed response variable. The GLM is further specified by the link function to linearize the relationship. Various link functions such as identity, log, inverse, inverse square, and square root were explored. The model with the minimum Akaike’s Information Criterion (AIC) or Bayesian Information Criterion (BIC) was selected as the best fitting model.
An alpha of 0.05 was used as the cutoff for significance. SPSS version 21 (IBM Corp., Armonk, NY) was used for statistical analysis.

Results
Characteristics of study countries
Characteristics of study countries are shown in Table 1. The median GGGI score for 153 countries was 0.706 (interquartile range [IQR], 0.664–0.736). The median score for educational attainment and health/survival among the GGGI subindices was close to 1 (0.992 [IQR, 0.956–0.999] and 0.974 [IQR, 0.969–0.979], respectively).

Relationship between GGGI and vertical transmission outcomes
GGGI score was significantly related to both hepatitis outcomes, three of the four HIV outcomes, and one syphilis outcome. For all outcomes, using GGGI rather than using GGGI’s subindices has built GLM models that better describe the outcomes.

Hepatitis virus
The median incidence of chronic hepatitis B and that of hepatitis C in under 5 years was 0.5 (IQR, 0.1–0.8) and 0.3 (IQR, 0.2–0.7) cases per 100,000, respectively (Table 1).

GLM with gamma family and square root link was selected as the best-fit model for the incidence of chronic hepatitis B. As the GGGI score increased, that is, as the gender gap decreased, the incidence of chronic hepatitis B decreased significantly ($p < 0.001$; Table 2). GLM with inverse family and log link was used to describe the incidence of chronic hepatitis C. GGGI score was also found to be a significant predictor of the incidence of chronic hepatitis C ($p < 0.001$; Table 2).

Human immunodeficiency virus
Information related to HIV was reported mainly in low- and middle-income countries, while HI countries were omitted (Table 1). The percentage of pregnant women with unknown HIV status and who have not received ART for PMTCT was 16% (IQR, 5–12) and 27% (IQR, 15–60), respectively. Infants with a median value of 49% (IQR, 30–76) were not diagnosed early, and the median of the final transmission rate was 15 (IQR, 10–23).

GLM with inverse family and identity link best fitted data on pregnant women with unknown HIV status. GGGI was significantly associated with the pregnant women with unknown HIV status ($p = 0.001$; Table 3). GLM for pregnant women who have not received ART for PMTCT showed that none of the evaluated predictors was significant (Table 3).

GLM with gamma family and identity link was best suited for both no early infant diagnosis and final transmission rate. The high GGGI scores were significantly associated with a decrease in both outcomes ($p = 0.027$ and $p = 0.005$, respectively; Table 3). In addition, as the percentage of SBA increased, the final transmission rate significantly decreased ($p = 0.006$; Table 3).

Syphilis
Maternal syphilis prevalence was 0.2% (IQR, 0.06–1.1). Both the percentage of no screening and no treatment were low (10% [IQR, 3–38] and 7% [IQR, 5–16], respectively). Congenital syphilis rate was 70 (IQR, 8–519) cases/100,000 (Table 1).

GLM with gamma family was used for four syphilis outcomes. The prevalence of maternal syphilis was significantly lower in HI countries than in LI countries.

Table 1. Characteristics of Study Countries

| Characteristic                                      | Countries (n = 153) |
|----------------------------------------------------|---------------------|
| GGGI scorea                                         | 0.706 (0.664–0.736) |
| Economic participation/opportunitya                 | 0.673 (0.598–0.736) |
| Educational attainmenta                             | 0.992 (0.956–0.999) |
| Health/survala                                      | 0.974 (0.969–0.979) |
| Political empowermenta                              | 0.189 (0.111–0.278) |
| SBA (%)a                                            | 97.95 (81.55–99.7)  |
| GNI per capita, Atlas method (USD)a                 | 6040 (2220–19,320) |
| Hla                                                 | 53 (34.6)           |
| UMIb                                                | 40 (26.1)           |
| LMBb                                                | 42 (27.5)           |
| Liob                                                | 18 (11.8)           |
| Incidence of chronic hepatitis B (cases/100,000)a   | 0.5 (0.1–0.8)       |
| Incidence of chronic hepatitis C (cases/100,000)a   | 0.3 (0.2–0.7)       |
| Pregnant women with unknown HIV status (%)a (n = 81)| 16 (5–52)           |
| Pregnant women who have not received ART for PMTCT (%)a (n = 81) | 27 (15–60) |
| No early infants diagnosis of HIV (%)a (n = 94)     | 49 (30–76)          |
| Final transmission rate of HIVa (n = 79)            | 15 (10–23)          |
| Maternal syphilis prevalence (%)a                   | 0.2 (0.06–1.1)      |
| No syphilis screening (%)a                          | 10 (3–38)           |
| No syphilis treatment (%)a                          | 7 (5–16)            |
| Congenital syphilis rate (cases/100,000 live births)a | 70 (8–519)          |

aMedian (interquartile range).  

b$n$ (%).  

ART, antiretroviral therapy; GGGI, Global Gender Gap Index; GNI, gross national income; Hl, high income; HIV, human immunodeficiency virus; LI, low income; LMI, lower-middle income; PMTCT, prevention of mother-to-child transmission; SBA, skilled birth attendant; UMI, upper-middle income.
Table 2. Generalized Linear Models for Outcomes of Hepatitis Virus

| GLM                                      | n  | Predictors                        | β   | 95% CI                     |
|------------------------------------------|----|----------------------------------|-----|----------------------------|
| Incidence of chronic hepatitis B (cases/100,000) | 134 | Intercept (β₀)                   | 2.83| 2.26 to 3.40               |
|                                          |    | GGGI (β₁)                        | −3.38| −4.18 to −2.58*            |
|                                          |    | SBA (β₂)                         | 0.004| 0.0003 to 0.007*           |
|                                          |    | LI (β₃)                          | 0   | Reference                  |
|                                          |    | LMI (β₄)                         | −0.032| −0.196 to 0.132            |
|                                          |    | UMI (β₅)                         | −0.081| −0.288 to 0.127            |
|                                          |    | HI (β₆)                          | −0.028| −0.239 to 0.183            |
|                                          |    | Predators                        | β   | 95% CI                     |
|                                          |    | GGGI (β₁)                        | −3.69| −4.81 to −2.58*            |
|                                          |    | SBA (β₂)                         | 0.051| 0.0003 to 0.007*           |
|                                          |    | LI (β₃)                          | 0   | Reference                  |
|                                          |    | LMI (β₄)                         | −0.032| −0.196 to 0.132            |
|                                          |    | UMI (β₅)                         | −0.081| −0.288 to 0.127            |
|                                          |    | HI (β₆)                          | −0.028| −0.239 to 0.183            |
| Incidence of chronic hepatitis C (cases/100,000) | 148 | Intercept (β₀)                   | 3.54| 1.79 to 5.28               |
|                                          |    | GGGI (β₁)                        | −7.65| −9.98 to −5.32*            |
|                                          |    | SBA (β₂)                         | 0.018| 0.0008 to 0.029*           |
|                                          |    | LI (β₃)                          | 0   | Reference                  |
|                                          |    | LMI (β₄)                         | −0.425| −1.042 to 0.191            |
|                                          |    | UMI (β₅)                         | −0.566| −1.315 to 0.183            |
|                                          |    | HI (β₆)                          | −0.576| −1.325 to 0.173            |

*p<0.05.

GLM, generalized linear model.

(p = 0.005; Table 4). Country income was a significant predictor of no syphilis screening and no syphilis treatment, and both ratios were significantly lower than those of LI countries in HI countries (p = 0.003 and p = 0.019, respectively; Table 4). Increasing GGGI scores and increasing SBA percentages also significantly reduced the ratio of no syphilis screening (p<0.001 and p = 0.09, respectively; Table 4).

Congenital syphilis rate was associated with country income. There has been a significant decrease in

Table 3. Generalized Linear Models for Outcomes of Human Immunodeficiency Virus

| GLM                                      | n  | Predictors                        | β   | 95% CI                     |
|------------------------------------------|----|----------------------------------|-----|----------------------------|
| Pregnant women with unknown HIV status (%) | 72  | Intercept (β₀)                   | 190.7| 92.0 to 289.5              |
|                                          |    | GGGI (β₁)                        | −198.5| −318.1 to −78.8*           |
|                                          |    | SBA (β₂)                         | −0.28| −0.74 to 0.19              |
|                                          |    | LI (β₃)                          | 0   | Reference                  |
|                                          |    | LMI (β₄)                         | −1.15| −12.1 to 9.82              |
|                                          |    | UMI (β₅)                         | 6.36 | −8.98 to 21.7              |
|                                          |    | HI (β₆)                          | 0.58| −38.1 to 39.3              |
| Pregnant women who have not received ART for PMTCT (%) | 72  | Intercept (β₀)                   | 13.8 | 5.7 to 21.8                |
|                                          |    | GGGI (β₁)                        | −10.2 | −21.5 to 1.1               |
|                                          |    | SBA (β₂)                         | −0.03 | −0.07 to 0.02              |
|                                          |    | LI (β₃)                          | 0   | Reference                  |
|                                          |    | LMI (β₄)                         | 1.42 | −0.41 to 3.25              |
|                                          |    | UMI (β₅)                         | 1.05 | −0.84 to 2.94              |
|                                          |    | HI (β₆)                          | −1.43| −3.14 to 0.27              |
| No early infant diagnosis (%)             | 59  | Intercept (β₀)                   | 191.3| 100.4 to 282.2             |
|                                          |    | GGGI (β₁)                        | −148.1| −279.4 to −16.7*           |
|                                          |    | SBA (β₂)                         | −0.54 | −1.12 to 0.04              |
|                                          |    | LI (β₃)                          | 0   | Reference                  |
|                                          |    | LMI (β₄)                         | 6.28 | −15.2 to 27.8              |
|                                          |    | UMI (β₅)                         | −0.94 | −24.5 to 22.7              |
|                                          |    | HI (β₆)                          | −14.4| −50.8 to 22.1              |
| Final transmission rate                   | 74  | Intercept (β₀)                   | 66.8 | 42.8 to 90.8               |
|                                          |    | GGGI (β₁)                        | −50.7 | −86.1 to −15.4*            |
|                                          |    | SBA (β₂)                         | −0.22 | −0.38 to −0.06*            |
|                                          |    | LI (β₃)                          | 0   | Reference                  |
|                                          |    | LMI (β₄)                         | 5.06 | −0.14 to 10.25             |
|                                          |    | UMI (β₅)                         | 2.01 | −3.55 to 7.57              |
|                                          |    | HI (β₆)                          | −2.56| −10.83 to 5.72             |

*p<0.05.
Table 4. Generalized Linear Models for Outcomes of Syphilis

| GLM                                                                 | n  | Predictors | β        | 95% CI       |
|---------------------------------------------------------------------|----|------------|----------|--------------|
| Maternal syphilis prevalence (%)                                    |    | Intercept (β₀) | 3.42     | -0.09 to 6.93 |
| (β₀ + β₁ × GGGI + β₂ × SBA + β₃ × country income) (Gamma family, log link) |    | GGGI (β₁)   | -2.34    | -7.23 to 2.55 |
| (β₀ + β₁ × GGGI + β₂ × SBA + β₃ × country income) (Gamma family, inverse link) |    | SBA (β₂)    | -0.02    | -0.04 to 0.004 |
| (β₀ + β₁ × GGGI + β₂ × SBA + β₃ × country income) (Gamma family, square root link) |    | LI (β₃)     | 0        | Reference     |
| (β₀ + β₁ × GGGI + β₂ × SBA + β₃ × country income) (Gamma family, log link) |    | LMI (β₄)    | -0.45    | -1.24 to 0.33 |
| (β₀ + β₁ × GGGI + β₂ × SBA + β₃ × country income) (Gamma family, log link) |    | UMI (β₅)    | -0.64    | -1.60 to 0.32 |
| HIV (β₆)                                                             |    | -1.37      | -2.33 to -0.41* |
| No syphilis screening (%)                                            |    | Intercept (β₀) | 16.8     | 12.5 to 21.2 |
| (β₀ + β₁ × GGGI + β₂ × SBA + β₃ × country income)² (Gamma family, identity link) |    | GGGI (β₁)   | -7.52    | -11.4 to -3.62* |
| (β₀ + β₁ × GGGI + β₂ × SBA + β₃ × country income) (Gamma family, identity link) |    | SBA (β₂)    | -0.06    | -0.10 to -0.02* |
| (β₀ + β₁ × GGGI + β₂ × SBA + β₃ × country income) (Gamma family, identity link) |    | LI (β₃)     | 0        | Reference     |
| (β₀ + β₁ × GGGI + β₂ × SBA + β₃ × country income) (Gamma family, identity link) |    | LMI (β₄)    | -1.29    | -3.01 to 0.43 |
| (β₀ + β₁ × GGGI + β₂ × SBA + β₃ × country income) (Gamma family, identity link) |    | UMI (β₅)    | -1.81    | -3.74 to 0.13 |
| HIV (β₆)                                                             |    | -2.93      | -4.84 to -1.01* |
| No syphilis treatment (%)                                            |    | Intercept (β₀) | 27.4     | 3.25 to 51.4 |
| (β₀ + β₁ × GGGI + β₂ × SBA + β₃ × country income) (Gamma family, identity link) |    | GGGI (β₁)   | 2.00     | -23.5 to 27.5 |
| (β₀ + β₁ × GGGI + β₂ × SBA + β₃ × country income) (Gamma family, identity link) |    | SBA (β₂)    | -0.10    | -0.33 to 0.13 |
| (β₀ + β₁ × GGGI + β₂ × SBA + β₃ × country income) (Gamma family, identity link) |    | LI (β₃)     | 0        | Reference     |
| (β₀ + β₁ × GGGI + β₂ × SBA + β₃ × country income) (Gamma family, identity link) |    | LMI (β₄)    | 1.57     | -8.29 to 11.4 |
| (β₀ + β₁ × GGGI + β₂ × SBA + β₃ × country income) (Gamma family, identity link) |    | UMI (β₅)    | -0.86    | -11.7 to 9.95 |
| HIV (β₆)                                                             |    | -12.8      | -23.5 to -2.11* |
| Congenital syphilis rate (cases per 100,000 live births)             |    | Intercept (β₀) | 0        | -0.04 to 0.004 |
| (β₀ + β₁ × GGGI + β₂ × SBA + β₃ × country income)⁻¹ (Gamma family, inverse link) |    | GGGI (β₁)   | 0        | -0.006 to 0.006 |
| (β₀ + β₁ × GGGI + β₂ × SBA + β₃ × country income)⁻¹ (Gamma family, inverse link) |    | SBA (β₂)    | 0        | -0.00001 to 0.00002 |
| (β₀ + β₁ × GGGI + β₂ × SBA + β₃ × country income)⁻¹ (Gamma family, inverse link) |    | LI (β₃)     | 0        | Reference     |
| (β₀ + β₁ × GGGI + β₂ × SBA + β₃ × country income)⁻¹ (Gamma family, inverse link) |    | LMI (β₄)    | 0.001    | -0.0004 to 0.0002 |
| (β₀ + β₁ × GGGI + β₂ × SBA + β₃ × country income)⁻¹ (Gamma family, inverse link) |    | UMI (β₅)    | 0.003    | 0.001 to 0.005* |
| HIV (β₆)                                                             |    | 0.009      | 0.005 to 0.014* |

*p < 0.05.

Congenital syphilis rates in UMI and HI countries compared to LI countries (p = 0.01 and p < 0.001, respectively; Table 4).

Discussion
This study investigated the association between gender equity and vertically transmitted infections at country level. The GGGI, an indicator of gender equity, was related with several outcomes of vertically transmitted infections. The high GGGI score, which means a decrease in the gender gap, was related to the improvement of vertical infection outcomes. The significant influence of GGGI was derived from an analysis that reflected SBA and country income, which are thought to affect vertical infections.

Vertical transmission of hepatitis B virus depends on the maternal hepatitis B e antigen (HBeAg) status, which is approximately 10–30% in HBeAg(−) carriers and considerably increases to 90% in HBeAg(+). Pregnant hepatitis B carriers can also benefit from receiving antivirals for PMTCT if they recognize their conditions. Mother-to-child transmission of hepatitis C virus is the leading cause of pediatric hepatitis C and can occur during intrauterine and peripartum period. Maternal ribonucleic acid (RNA) viral load > 6 log IU/mL was identified as an important determinant of vertical transmission. Currently, there is no proven safe and effective approach for the PMTCT of hepatitis C virus. Nevertheless, awareness of hepatitis C is expected to reduce the vertical propagation of hepatitis C. In particular, unlike HIV that develops severe symptoms, hepatitis virus carriers may not know their status. Self-awareness of viral hepatitis status was significantly lower in people with less education. Thus, a high GGGI score means improvement in women’s educational attainment and would have been associated with a decrease in the incidence of chronic hepatitis B and C in under 5 years in this study.

HIV is one of the world’s most serious health challenges. Fortunately, antiviral treatment has benefited
from preventing the virus from mother-to-child transmission.\textsuperscript{43,44} However, gender inequality restricted pregnant women from knowing their HIV status, and infants from receiving a virologic test within 2 months of birth in this study. For this reason, the final transmission rate would have increased with lower GGGI scores. Women with decision-making power tended to have a higher likelihood of preventing vertical infection of HIV.\textsuperscript{27} Also, gender inequality may make it impossible to negotiate with partners infected with HIV or use of condoms.\textsuperscript{45} Similarly gender inequality has been reported to be linked to under-five mortality due to HIV transmission in another study.\textsuperscript{11}

Syphilis vertical transmission caused congenital syphilis and neonatal deaths in 76.8% of untreated pregnant patients.\textsuperscript{46} Congenital syphilis remains the most common vertically transmitted infection, which was more frequently reported than perinatal HIV infections.\textsuperscript{46,47} However, latent syphilis is hard to be aware of due to the absence of clinical symptoms, which continues to cause mother-to-child transmission of syphilis.\textsuperscript{46} Early initiation of antenatal care and antenatal syphilis diagnosis could prevent adverse pregnancy outcomes.\textsuperscript{48} For this reason, recognition, appropriate maternal testing, and treatment during the pregnancy have been suggested.\textsuperscript{46,47} Gender equity improved syphilis screening coverage during pregnancy and might improve awareness of syphilis. Unlike the hypothesis, however, the gender gap had no significant association with the rest of the syphilis indicators. Instead, country income was significantly linked to maternal syphilis prevalence, syphilis screening coverage, syphilis treatment coverage, and congenital syphilis rate.

Besides gender equity, SBA was associated with final transmission rate of HIV and syphilis screening. SBA is a key indicator in measuring progression toward advanced women’s health.\textsuperscript{49} In a previous study, countries with the highest SBA had significant reduction in neonatal mortality.\textsuperscript{50} Furthermore, reduction in accessibility to antenatal care and SBA limits the chances to provide PMTCT services.\textsuperscript{49,51} Therefore, high SBA would have had a positive effect on HIV and syphilis outcomes.

This study has several limitations. First, this country-level study ignored personal factors and consequences. There is no information on maternal infectious status and receiving PMTCT at individual level, which are important factors of vertically transmitted infections. Second, the year in which each of the indicators was investigated, including the GGGI data, is not completely the same. Finally, there may be some confounding factors that were not sufficiently considered in this study.

**Conclusion**

A lower GGGI score was associated with higher vertical transmission of hepatitis and HIV. Thus, the improvement of gender equity might prevent the mother-to-child transmission and further contribute to the eradication of these viruses. From a public health perspective, policy support will be needed to reduce gender gaps. It would be worthwhile to elucidate the underpinning mechanisms or verify the results of this study through future intervention studies that reduce the gender gap at the individual level.

**Author Disclosure Statement**

No competing financial interests exist.

**Funding Information**

This work was supported by the Ministry of Education (no grant number).

**References**

1. Partners in Population and Development (PPD). Promoting Women’s Empowerment for Better Health Outcomes for Women and Children. Available at https://www.who.int/pmnch/knowledge/publications/strategybriefs/sb_gender.pdf Accessed October 3, 2019.
2. Choe SA, Cho SI, Kim H. Gender gap matters in maternal mortality in low and lower-middle-income countries: a study of the global Gender Gap Index. Glob Public Health. 2017;12:1065–1076.
3. The United Nations. Goal 5: Achieve gender equality and empower all women and girls. Available at https://www.un.org/sustainabledevelopment/gender-equality Accessed October 3, 2019.
4. PerezNieto P. What Can Gender Indices Tell Us About Gender Norms That Affect Adolescent Girls. London: Overseas Development Institute, 2015.
5. Lancet. Gender equity is the key to maternal and child health. 2010;375:1939.
6. King TL, Kavanagh A, Scovelle AJ, et al. Associations between gender equity and health: a systematic review. Health Promot Int. 2018;33:27–41.
7. Lan CW, Tavrow P. Composite measures of women’s empowerment and their association with maternal mortality in low-income countries. BMC Pregnancy Childbirth. 2017;17:337.
8. Dalal K, Shabnam J, Andrews-Chavez J, et al. Economic empowerment of women and utilization of maternal delivery care in bangladesh. Int J Prev Med. 2012;3:628–636.
9. Cui Y, Zhang Q, Yang L, et al. Effect of married women’s beliefs about gender equity on their use of prenatal and delivery care in rural China. Int J Gynaecol Obstet. 2010;111:148–151.
10. Singh K, Bloom S, Haney E, et al. Gender equality and childbirth in a health facility: Nigeria and MDGs. Afr J Reprod Health. 2012;16:123–129.
11. Brinda EM, Rajkumar AP, Enemark U. Association between gender inequality index and child mortality rates: a cross-national study of 138 countries. BMC Public Health. 2013;13:97.
12. Varkey P, Kureshi S, Lesnick T. Empowerment of women and its association with the health of the community. J Womens Health (Larchmt). 2010;19:71–76.
13. Iqbal N, Gkiouleka A, Milner A, et al. Girls’ hidden penalty: analysis of gender inequality in child mortality with data from 195 countries. BMJ Glob Health. 2018;3:e001028.
14. de Looze M, Madkour AS, Hujsis T, et al. Country-level gender equality and adolescents’ contraceptive use in Europe, Canada, and Israel: findings from 33 countries. Perspect Sex Reprod Health. 2019;51:43–53.

15. Decker MR, Kalamar A, Tuncalp O, et al. Early adolescent childbearing in low- and middle-income countries: associations with income inequality, human development and gender equality. Health Policy Plan. 2017;32:277–282.

16. Xu Y, Bentley RJ, Kavanagh AM. Gender equity and contraceptive use in China: an ecological analysis. Women Health. 2011;51:739–758.

17. Moore DL, Allen UD. HIV in pregnancy: identification of intrapartum and perinatal HIV exposures. Paediatr Child Health. 2019;24:42–49.

18. Cheung KW, Seto MYT, Lao TT. Prevention of perinatal hepatitis B virus transmission. Arch Gynecol Obstet. 2019;300:251–259.

19. Lin JS, Eder ML, Bean SI. Screening for syphilis infection in pregnant women: updated evidence report and systematic review for the US preventive services task force. JAMA. 2018;320:918–925.

20. Leung J, Peacock A, Colledge S, et al. A global meta-analysis of the prevalence of HIV, hepatitis C virus, and hepatitis B virus among people who inject drugs do gender-based differences vary by country-level indicators? J Infect Dis. 2019;220:78–90.

21. Thapa R, Yang Y, Kang JH, et al. Empowerment as a predictor of HIV testing among married women in Nepal. J Assoc Nurses AIDS Care. 2019;30:563–574.

22. Singh K, Luseno W, Haney E. Gender equality and education: increasing the uptake of HIV testing among married women in Kenya, Zambia and Zimbabwe. AIDS Care. 2013;25:1452–1461.

23. Tenny PE, Mhloyi M, Masuva TB, et al. Gender equity and HIV/AIDS prevention: comparing gender differences in sexual practice and beliefs among Zimbabwe university students. Int Q Community Health Educ. 2005;24:29–43.

24. Macpherson EE, Richards E, Namakhoma J, et al. Gender equity and sexual and reproductive health in Eastern and Southern Africa: a critical overview of the literature. Glob Health Action. 2014;7:23717.

25. Richardson ET, Collins SE, Kung T, et al. Gender inequality and HIV transmission: a global analysis. J Int AIDS Soc. 2014;17:19035.

26. Bloom SS, Agrawal A, Singh KK, et al. Gender inequality and the risk of HIV transmission. Adv Neonatal Care. 2018;18:330–340.

27. Ford C, Chibwesha CJ, Winston J, et al. Women’s decision-making and AIDS prevention: comparing gender differences in sexual practice and beliefs among Zimbabwean married couples. Int J AIDS Soc. 2015;27:168–175.

28. Ford C, Chibwesha CJ, Winston J, et al. Women’s decision-making and uptake of services to prevent mother-to-child HIV transmission in Zambia. AIDS Care. 2018;30:426–434.

29. World Economic Forum. The Global Gender Gap Report 2020. Geneva, Switzerland: World Economic Forum, 2019.

30. The World Bank. GNI per capita, Atlas method (current US$). Available at https://data.worldbank.org/indicator/NY.GNP.PCAP.CD Accessed September 21, 2020.

31. The World Bank. Births attended by skilled health staff (% of total). Available at https://data.worldbank.org/indicator/SH.STA.BRTC.ZS Accessed September 21, 2020.

32. Institute of Health Metrics and Evaluation. IHME Hepatitis Facts. Available at https://hepatitis.ihme.services/trends?age_group_id=1&cause_id=2900&gender_id=3&location_id=1&measure_id=6&metric_id=3 Accessed September 21, 2020.

33. World Health Organization. HIV Country Profile: 2019. Available at https://cfs.hivvc.org/country-factsheet.html Accessed September 21, 2020.

34. Korenromp EL, Rowley J, Alonso M, et al. Global burden of maternal and congenital syphilis and associated adverse birth outcomes-Estimates for 2016 and progress since 2012. PLoS One. 2019;14:e0211720.

35. Ng VKY, Cribbie RA. Using the gamma generalized linear model for modeling continuous, skewed and heteroscedastic outcomes in psychology. Curr Psychol. 2017;36:225–235.

36. Akaife H. A new look at the statistical model identification. IEEE Trans Automat Contr. 1974;19:716–723.

37. Schwarz GE. Estimating the dimension of a model. Ann Stat. 1978;6:461–464.

38. Isaacs D, Kilham HA, Alexander S, et al. Ethical issues in preventing mother-to-child transmission of hepatitis B by immunisation. Vaccine. 2011;29:6159–6162.

39. Pott HJ, Theodoros M, de Almeida Vespoli J, et al. Mother-to-child transmission of hepatitis C virus. Eur J Obstet Gynecol Reprod Biol. 2018;224:125–130.

40. Nwahiri A, Schillie S, Bultreys M, et al. Hepatitis C virus infection in children: how do we prevent it and how do we treat it? Expert Rev Anti Infect Ther. 2018;16:689–694.

41. Gentile I, Zappulo E, Buonorno AR, et al. Prevention of mother-to-child transmission of hepatitis B virus and hepatitis C virus. Expert Rev Anti Infect Ther. 2014;12:775–782.

42. Ahn HR, Cho SB, Chung U, et al. Socioeconomic differences in self- and family awareness of viral hepatitis status among carriers of hepatitis B or C in rural Korea. Am J Infect Control. 2018;46:328–332.

43. Hurst SA, Appelgren KE, Kourtis AP. Prevention of mother-to-child transmission of HIV type 1: the role of neonatal and infant prophylaxis. Expert Rev Anti Infect Ther. 2015;13:169–181.

44. Lynch NG, Johnson AK. Congenital HIV: prevention of maternal to child transmission. Adv Neonatal Care. 2018;18:330–340.

45. Hasnain M. Cultural approach to HIV/AIDS harm reduction in Muslim countries. Harm Reduct J. 2005;2:23.

46. Rac MW, Revell PA, Eppea CS. Syphilis during pregnancy: a preventable threat to maternal-fetal health. Am J Obstet Gynecol. 2017;216:8401.

47. Kwak J, Lamprecht C. A review of the guidelines for the evaluation and treatment of congenital syphilis. Pediatr Ann. 2015;44:e108–e114.

48. Zhang X, Yu Y, Yang H, et al. Surveillance of maternal syphilis in China: pregnancy outcomes and determinants of congenital syphilis. Med Sci Monit. 2018;24:7772–7779.

49. Moreira F, Aung KD, Nidoro T, et al. Participation of traditional birth attendants in prevention of mother-to-child transmission of HIV services in two rural districts in Zimbabwe: a feasibility study. BMC Public Health. 2008;8:401.

50. Bellizzi S, Sobel HL, Mathai M, et al. Does place and attendance at birth improve early neonatal mortality? Secondary analysis of nine Demographic and Health Surveys. BJOG. 2017;124:1558–1565.

51. Silva Neto SED, Silva S, Sartori AMC. Syphilis in pregnancy, congenital syphilis, and factors associated with mother-to-child transmission in Itapeva, Sao Paulo, 2010 to 2014. Rev Soc Bras Med Trop. 2018;51:819–826.